# Good Registration Management
## Experiences Sharing from Center for Drug Evaluation-Reviewer

Chi-Hsun Chen, M.D.

Senior Team Leader/Medical Reviewer, Division of New Drug

Center for Drug Evaluation (CDE), Taiwan

財團法人醫藥品查驗中心
Center for Drug Evaluation, Taiwan

1st Thailand GRM Conference
Bangkok, Thailand, June 26-28, 2018

# Disclaimer

This presentation was not officially cleared, and the views offered here do not necessarily represent the official positions at MOHW, including TFDA.

# Outline

- Regulatory Framework in Taiwan
- Experiences Related to Good Review Practices (GRevP)

# Regulatory Framework in Taiwan

財團法人醫藥品查驗中心
Center for Drug Evaluation,Taiwan

# Agencies for Drug Regulation in Taiwan

- **Taiwan Food and Drug Administration (TFDA)**
  - Subordinate to Ministry of Health & Welfare (MoHW)
  - Official regulatory authority for licensing new drugs
  - Review the administrative documents
- **Center for Drug Evaluation (CDE)**
  - Established in 1998
  - A non-governmental organization (NGO)
  - Responsible for review of technical documents

# Taiwan Food and Drug Administration (TFDA)




**Workforce:**
**All: 1,131**
**Division of medicinal products: 132**
**Budget (2014): US$74million**

財團法人醫藥品查驗中心
Center for Drug Evaluation,Taiwan

# Center for Drug Evaluation (CDE), Taiwan




財團法人醫藥品查驗中心
Center for Drug Evaluation, Taiwan

# Relationship between TFDA & CDE, NDA as Example




財團法人醫藥品查驗中心
Center for Drug Evaluation, Taiwan

# Experiences Related to Good Review Practices (GRevP)

財團法人醫藥品查驗中心
Center for Drug Evaluation,Taiwan

# Managing the Review – Project Management

- A Project manager (PM) for each case
- Currently 28 PMs, belong to Division of General Affairs
- Responsibilities
  (1) Arrange meetings
  (2) Issue deadline of review report to each reviewer
  (3) Communication to applicants
- Periodic meeting for monitoring the review progress
  - division directors, team leaders,

# Managing the Review - Timelines of NDA Review



# Managing the Review – Quality Management

- Periodic group meetings: case discussion
- Hierarchical review and decision making:
  Primary reviewer
  Secondary reviewer (or team leader)
  Division director
  Deputy executive director
  Executive director
- An outside expert joins the NDA review meeting for NCE

# Managing the Review

## Standard Operation Procedures (SOP)

- Currently 37 SOPs
- Revised every 2 years
- IND, NDA, BSE, ANDA, DMF, API, RMP, Medical device, Consultation, HTA……etc.

財團法人醫藥品查驗中心

Standard Operating Procedure

| | | |
|---|---|---|
| **Title:** | **Document Code S.O.P.** | **Code No.** |
| | **Effective date:** | **Superseded:** |
| **Document type :** | | **Total pages** |
| **Written by /Date:** | **Reviewed by / Date :** | |
| **Checked by Director of Regulatory Affairs /Date :**<br>**Checked by Director of New Drug /Date :**<br>**Checked by Director of Pharmaceutical Science /Date :**<br>**Checked by Director of Medical Devices /Date :**<br>**Checked by Director of Center of Consultation /Date :**<br>**Checked by Director of Heath Technology Assessment /Date :**<br>**Checked by Director of general Affairs /Date :** | | |
| **Checked by Deputy Executive Director/ Date :** | | |
| **Approved by Executive Director / Date :** | | |
| **Summary of changes :** | | |

# Managing the Review - Validation

- GRevP 4.4
  Validation involves an examination of the application to ensure that it is well-organized and that all the required forms and relevant documents have been submitted.
- Refuse to file (RTF) procedure for NDA and ANDA
  - ✓ NDA
    (1) Official Announcement on Oct. 27, 2016; effective since Jan. 01, 2017
    (2) Checklist (CTD format as major requirement), process ongoing…….
    (3) Deficiencies will be notified to sponsors
    (4) One chance of re-submission; application fee not be refunded
  - ✓ ANDA
    (1) Official Announcement on Dec. 14, 2016; effective since Jan. 01, 2017
    (2) Checklist (CTD format as major requirement)
    (3) Deficiencies will be notified to sponsors
    (4) Partial refund of application fee for cases of RTF

# Review Personnel of CDE (as of end of 2017)

- Reviewers' academic professions include medical (physicians), pharmaceutical science, pharmacokinetics, chemistry, pharmacology, statistics, biochemistry, biotechnology, bioengineering, medical engineering, pharmacoeconomics, pharmacotherapy, epidemiology, etc.
- Total 251 reviewers
  - 31 MD reviewers (physicians)
  - 50 Reviewers with PhD degree
  - 153 Reviewers with master degree

# Reviewer Training

- Mainly on-Job training
  (1) secondary reviewers supervise primary junior reviewers for each case
  (2) There is a mentor for each junior reviewer.
  (3) Case discussion for junior reviewers; one-on-one teaching by an outside expert
- On-line training courses
  (1) 262 topics covering various fields (CMC, P/T, statistics, medical device…….)
  (2) Pre-recorded by senior reviewers, contain slides and speakers' oral presentation
  (3) More topics will be available in the future.
- Regular group meetings
  (1) Once per week for clinical division
  (2) Once per month for CMC and PK sections
- Seminars – invite experts from academy, other agencies, industries, etc.

# Conducting the Review
# - Classification of Submitted NDA

- **NCE** (new chemical entity), biologics, biosimilar, new vaccine
- **New combination**
- **New formulations**: e.g. Tablet → IV injection, Solution for injection → Liposome…..etc.
- **New indication**
- **New strength**: e.g. 30mg/tab → 5mg/tab
- **New posology** (including rules of dose adjustment)

# Conducting the Review
# - Multidisciplinary Review Team

**For NDA of NCE, new biologics or biosimilar**

- Review Team (full review team)
  - **Team leader**
  - Project manager
  - Clinical reviewer
  - Statistic reviewers
  - Pharmacology/Toxicology (P/T) reviewers
  - PK reviewers
  - CMC reviewers
  - Medical device reviewers (if needed)

# Thanks for Your Attention

財團法人醫藥品查驗中心
Center for Drug Evaluation,Taiwan